Are peptides legal now? What the new HHS policy really means

An illustration of vaccine glass vials with blue caps arranged in rows. — Andrei Kuzmik // Shutterstock
An illustration of vaccine glass vials with blue caps arranged in rows. — Andrei Kuzmik // Shutterstock

Six popular peptides may soon be easier to get through a doctor and a licensed pharmacy. In late October, the Department of Health and Human Services (HHS), which oversees the FDA, announced an interim policy saying it won’t take certain enforcement actions against physicians and pharmacies preparing BPC-157, TB-500, KPV, MOTS-c, epitalon, and Semax — provided they meet specific conditions.

The policy doesn’t legalize these peptides or grant FDA approval. It doesn’t mean they work the way an influencer promised on TikTok or give every online peptide seller a green light. It does change the government’s approach to enforcing existing rules while the FDA considers their longer-term status.

Hone Health, a physician-led longevity clinic, breaks down what changed, what didn’t, and what it means if you’re curious about peptides.

Key Takeaways:

  • Six peptides that purport to combat aging, build muscle, and more just got easier to access.
  • The FDA hasn't approved them; it just won’t take enforcement action against pharmacies preparing these peptides if they follow a set of strict rules.
  • The agency says the interim policy will improve safety and suppress gray-market production.

Why Did HHS Issue This Policy?

Americans are already using peptides, short chains of amino acids that act as signaling molecules in the body. Some peptide medications, including insulin and certain GLP-1 drugs, are FDA-approved; this policy covers six that aren’t.

Among 476 current or past users who answered a product-use question in Hone Health’s May 2026 survey, 18% reported using BPC-157, 16% TB-500, and 18% the combination dubbed the “Wolverine Stack.” People seek out these peptides for tissue repair and injury recovery, though they aren’t FDA-approved for those uses.

“People are not going to stop using peptides. That genie is out of the bottle,” says Elizabeth Yurth, M.D., a Hone-affiliated physician and co-founder of the Boulder Longevity Institute and International Peptide Society. Yurth has prescribed a range of peptides for nearly 10 years and testified at July’s FDA advisory meeting in support of compounding access to BPC-157 and TB-500. "The real risk with peptides has never been the molecule. It's not knowing what's actually in the vial. This policy finally gives patients a way to get the real thing, tested for identity and purity, with a physician watching how they respond."

The risk Yurth is referring to comes from the fact that many products sold online are labeled “for research use only,” meaning they aren’t intended for human treatment. Buyers have no reliable way to verify their ingredients, concentration, or manufacturing standards.

HHS aims to steer people away from that uncertainty and toward physicians and licensed pharmacies that follow sourcing and testing requirements. Medical oversight matters to respondents: In a separate Hone survey question, nearly 90% of 625 respondents said involvement from a licensed medical provider would significantly or somewhat increase their trust in and willingness to try peptide therapy. Respondent counts vary because different questions went to different groups.

There is disagreement, however, about whether the evidence supports expanded access. In July, the FDA’s outside advisory panel recommended allowing the six peptides in compounding. The FDA’s drug-review center, CDER, recommended against listing all six, citing insufficient evidence of safety and effectiveness.

Which Peptides Are Included?

The HHS policy covers six peptides in specific forms: BPC-157 (injection, oral, or topical), TB-500 (injection), MOTS-c (injection), epitalon (injection in intermittent courses), KPV (oral or topical), and Semax (nasal).

Each product must contain only one active ingredient. A blended BPC-157/TB-500 vial wouldn’t qualify. That doesn’t take the Wolverine Stack off the table — it just means a physician will have to prescribe them separately, subject to the policy’s other conditions and state requirements.

How Can You Get These Peptides?

Compounding pharmacies have rules about which ingredients they can use to prepare customized medications. These six don’t currently qualify, but HHS says it won’t take certain enforcement actions against providers preparing them under its conditions.

You’ll need a prescription from a physician. The policy covers traditional patient-specific compounding under Section 503A of federal law. It does not cover Section 503B outsourcing facilities, which can supply compounded medications without prescriptions for individually identified patients.

It also doesn’t bind state regulators. State pharmacy boards can still restrict access, so availability may differ depending on where you live.

Some longevity, wellness, and sports medicine practices already offer peptide treatment.

What Makes These Peptides Different From Ones Sold Online?

Unlike the gray market — with its mystery vials and DIY dosing — this pathway comes with sourcing rules, quality checks, and medical oversight.

Image
A table comparing gray-market peptides and peptides under the HHS draft policy.
Hone Health


These requirements don’t amount to FDA approval. The agency doesn’t review compounded medications for safety, effectiveness, or quality before they reach patients.

What Should You Ask Your Physician About Peptides?

Sourcing and testing requirements can’t establish whether a peptide will address your symptoms or reveal every possible side effect. The amount and quality of human research vary by peptide. Ask your physician:

  • On what basis do you recommend this peptide for my specific concern?
  • What are the known risks, and could my health history or medications make it unsuitable?
  • Are there established treatments with stronger evidence?
  • How will we know it’s helping, and when would we stop if it isn’t?
  • What side effects require a call or urgent care?

What’s Next for Peptides?

Public comments are scheduled to close on Nov. 13, 2026. Feedback could inform changes to the policy and the FDA’s longer-term decisions.

The FDA may propose adding some or all six peptides to its list of ingredients that pharmacies can use in customized medications. That requires a separate public review process; no deadline has been announced.

Before the end of February 2027, an outside FDA panel is also expected to review five other peptides: LL-37, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF. Its recommendations won’t automatically make them available or FDA-approved.

HHS can revise or withdraw its policy if safety or quality problems emerge, so access could change.

This story was produced by Hone Health and reviewed and distributed by Stacker.